Dr. Reddy's Laboratories Limited (NYSE:RDY) Shares Acquired by West Family Investments Inc.

West Family Investments Inc. boosted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 481.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 76,936 shares of the company's stock after buying an additional 63,711 shares during the period. West Family Investments Inc.'s holdings in Dr. Reddy's Laboratories were worth $1,215,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Farther Finance Advisors LLC increased its position in shares of Dr. Reddy's Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company's stock worth $36,000 after purchasing an additional 137 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in Dr. Reddy's Laboratories during the 3rd quarter worth about $60,000. Van ECK Associates Corp raised its stake in shares of Dr. Reddy's Laboratories by 64.3% during the 3rd quarter. Van ECK Associates Corp now owns 823 shares of the company's stock valued at $64,000 after buying an additional 322 shares during the last quarter. POM Investment Strategies LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 400.0% in the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after buying an additional 1,820 shares during the period. Finally, Glenmede Trust Co. NA purchased a new stake in shares of Dr. Reddy's Laboratories in the third quarter worth about $207,000. 3.85% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. StockNews.com downgraded shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, December 6th. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a report on Thursday, December 19th.

Dr. Reddy's Laboratories Stock Performance

NYSE:RDY traded down $0.14 during mid-day trading on Monday, reaching $12.78. 187,983 shares of the stock were exchanged, compared to its average volume of 1,232,792. The stock has a market capitalization of $10.66 billion, a P/E ratio of 20.36 and a beta of 0.48. Dr. Reddy's Laboratories Limited has a 1 year low of $12.62 and a 1 year high of $16.89. The company has a 50 day simple moving average of $14.18 and a 200-day simple moving average of $14.92. The company has a quick ratio of 1.38, a current ratio of 1.92 and a debt-to-equity ratio of 0.02.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Dr. Reddy's Laboratories Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.